Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study
about
Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesAIDS-defining illnesses among patients with HIV in Singapore, 1985 to 2001: results from the Singapore HIV Observational Cohort Study (SHOCS)Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsCost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failurePublic-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland comparedHighly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanLongitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage TherapyEstimating the potential pool of HIV-infected deceased organ donors in the United StatesProfound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionExcluding pregnancy among women initiating antiretroviral therapy: efficacy of a family planning job aid.Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection.Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.Creating and validating an algorithm to measure AIDS mortality in the adult population using verbal autopsy.Epidemiological link between low cholesterol and suicidality: a puzzle never finished.Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.HIV and combination therapy: meeting the challenge of a new era.The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in JapanProvider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIVSalvage treatment against human immunodeficiency virus.Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross-sectional study.Effect of early versus deferred antiretroviral therapy for HIV on survival.Antiretroviral combination therapy and HIV infection. Such treatment improved CD4 counts in Scottish patients.High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment.Hospitalizations in a cohort of HIV patients in Australia, 1999-2007Women and HIV--revisited ten years on.Palliative care for HIV disease in the era of highly active antiretroviral therapy.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.Rapid screening of HIV reverse transcriptase and integrase inhibitors.Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.Efavirenz: a pharmacoeconomic review of its use in HIV infection.Effective HIV treatment and the employment of HIV(+) adults.Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland
P2860
Q24514773-DECE217F-E0B6-4A8D-B1D3-2C2E82D65A3DQ24597052-D5EAF92E-1C78-4CDB-B96D-C19667F18991Q24656950-7488DC7D-32EF-43F3-A571-0C963E408392Q24802044-D977647E-7658-4DAF-A700-EB6ADDD81F71Q28069383-FE67A05C-B451-42DD-A950-BC1D3BBD8F7FQ28469116-A77F8B1A-A760-47BD-B607-CD80E8821638Q28473120-FD42DDFE-40BC-4848-985C-F6E749B65DBDQ28537608-67DE3146-9991-4130-8F8D-664076CF45E5Q28547874-BB250A3E-4B32-4ECF-B38C-381F73257B39Q28743880-5BE4DC61-FF54-4BF5-A7AD-33D530D6EE06Q28748901-E8249A02-482C-4C5D-B1F3-86E501F47072Q30494675-C9F948AA-A85B-43F9-8BDB-6C88F5DF0ECFQ30975363-7EEFC412-D857-4B39-8C0E-483D9B2D0781Q31811573-D6B534A1-DB68-4344-B18E-4D6F2306E9FDQ33252476-14FBCD1A-1A90-4470-8E7D-8B5465BE6F73Q33352441-598739A8-18EF-4E8F-BAF8-C94C9073D2F4Q33460434-B6190124-0993-4B65-B718-844D0FBA53FEQ33543387-1E191AE6-6BF8-4463-8A6C-7E3A7071C3CDQ33593774-292BC3B2-D852-4CD6-B406-FEECBFA59778Q33703513-A44C8D4B-AFAF-490D-AB45-76351A920124Q33730185-0934F221-8AE2-4787-A25D-4C35C06FEE26Q33753410-99167D24-B954-46A1-8E12-9E9687EFC1F7Q33789114-77070D08-40D3-4D87-845F-4928ADD1488EQ33792028-CDB284CF-A0C7-498C-BC43-34EA4FA13DA2Q33796791-A668D1E9-2074-4F9E-95B6-57B7B73D7CFFQ33876965-C3DF1169-67F7-42B9-BC6F-E4F381D9FEFCQ33888740-8466B7E6-DC37-43E5-9CBC-B592577BC379Q33924662-398AE0DB-9B1F-4FF8-A47B-D6E8EF2BF4EEQ33926171-E888F39F-2F16-47A0-857B-B6F55A75F2B6Q33944367-57280FAE-AA82-41AB-9B76-07B97784CBDFQ33979107-98D8F105-AB34-456B-8D95-46551E182620Q33982056-D8477C41-6DD5-4036-9ADD-A063A3E108E2Q34040005-12E970DC-2AE4-44D7-BD0A-0DE00245396AQ34113502-54851507-E6A5-4211-ABCE-766EE4094576Q34193340-67990E0D-EAF3-452B-B902-337B065E807FQ34208678-C44D141D-3B5B-4AB2-918C-CC427180B9CFQ34268304-53F4308C-AE55-44A5-95A4-16E6CA984153Q34336905-98C10222-1B48-41B2-AF0F-DE51236CF9DBQ34537487-5BBDB251-F583-4224-B3D0-B8397046DC9AQ34664047-ED151F3C-EFF5-496D-A047-0C81D5858E97
P2860
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Impact of new antiretroviral c ...... study. Swiss HIV Cohort Study
@ast
Impact of new antiretroviral c ...... study. Swiss HIV Cohort Study
@en
type
label
Impact of new antiretroviral c ...... study. Swiss HIV Cohort Study
@ast
Impact of new antiretroviral c ...... study. Swiss HIV Cohort Study
@en
prefLabel
Impact of new antiretroviral c ...... study. Swiss HIV Cohort Study
@ast
Impact of new antiretroviral c ...... study. Swiss HIV Cohort Study
@en
P2093
P1433
P1476
Impact of new antiretroviral c ...... study. Swiss HIV Cohort Study
@en
P2093
Battegay M
Francioli P
Hirschel B
Malinverni R
Rickenbach M
Vernazza P
P304
P356
10.1136/BMJ.315.7117.1194
P407
P577
1997-11-01T00:00:00Z